Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

This is a review of Plasmodium vivax epidemiology, pathogenesis, disease presentation, treatment and innovations in control and elimination. Here, we examine the recent literature and summarize new advances and ongoing challenges in the management of P. vivax . P. vivax has a complex life cycle in the human host which impacts disease severity and treatment regimens. There is increasing data for the presence of cryptic reservoirs in the spleen and bone marrow which may contribute to chronic vivax infections and possibly disease severity. Methods to map the geospatial epidemiology of P. vivax chloroquine resistance are advancing, and they will inform local treatment guidelines. P. vivax treatment requires an 8-aminoquinoline to eradicate the dormant liver stage. Evidence suggests that higher doses of 8-aminoquinolines may be needed for radical cure of tropical frequent-relapsing strains. P. vivax is a significant global health problem. There have been recent developments in understanding the complexity of P. vivax biology and optimization of antimalarial therapy. Studies toward the development of best practices for P. vivax control and elimination programs are ongoing. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.


Nazia Khan, Johanna P Daily. Update on pathogenesis, management, and control of Plasmodium vivax. Current opinion in infectious diseases. 2022 Oct 01;35(5):404-409

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36066361

View Full Text